Akihiro Tsuji

Akihiro Tsuji

Auto-generated profile, based on publicly available information

Akihiro Tsuji

National Cerebral and Cardiovascular Center

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2019 in International Journal of Cardiology
Verified
Journal Article
Closed access
RARyotaro Asano
Ryotaro Asano
TOTakeshi Ogo
Takeshi Ogo
KOKeiko Ohta-Ogo
Keiko Ohta-Ogo
SFShigefumi Fukui
Shigefumi Fukui
ATAkihiro Tsuji
Akihiro Tsuji
SYSatoshi Yasuda
Satoshi Yasuda

1 October 2016 in International Journal of Cardiology
Verified
Journal Article
Closed access
PDF file
ATAkihiro Tsuji
Akihiro Tsuji
TOTakeshi Ogo
Takeshi Ogo
JUJin Ueda
Jin Ueda
SFShigefumi Fukui
Shigefumi Fukui
YMYoshiaki Morita
Yoshiaki Morita
SYSatoshi Yasuda
Satoshi Yasuda

6 August 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
TKTakatoyo Kiko
Takatoyo Kiko
RARyotaro Asano
Ryotaro Asano
TITomohiko Ishibashi
Tomohiko Ishibashi
HEHiroyuki Endo
Hiroyuki Endo
NNNaruhiro Nishi
Naruhiro Nishi
TOTakeshi Ogo
Takeshi Ogo
Background: Ring finger protein 213 ( RNF213 ) p.Arg4810Lys is a susceptibility gene for moyamoya disease, peripheral pulmonary artery stenosis (PPS), and other vascular diseases and thrombosis. We investigated the prevalence and clinical characteristics of RNF213 variant carriers diagnosed with chronic thromboembolic pulmonary hypertension (CTEPH). Methods and Results: We retrospectively analyzed the prevalence of the RNF213 p.Arg4810Lys variant in patients diagnosed with CTEPH (n=112) and PPS (n=10). Clinical and angiographic characteristics were evaluated between RNF213 variant carriers diagnosed with CTEPH and noncarriers with CTEPH and homozygous variant carriers with PPS. Eight heterozygous RNF213 p.Arg4810Lys variant carriers (7.1%) were identified among patients diagnosed with CTEPH, while 5 patients with PPS (50%) carried the homozygous variant. The clinical characteristics of heterozygous variant carriers with CTEPH were not remarkably different from those of noncarriers with CTEPH. All heterozygous variant carriers with CTEPH showed webs/bands lesions at the segmental/subsegmental level, with 75% showing distal tortuous vessels. None of the heterozygous variant carriers with CTEPH exhibited the string‐of‐beads pattern or elongated stenosis. Homozygous variant carriers with PPS showed the string‐of‐beads pattern, elongated stenosis, and distal tortuous vessels without webs/bands lesions. Conclusions: A subset of patients diagnosed with CTEPH (7.1%) carried the heterozygous RNF213 p.Arg4810Lys variant. Clinical and angiographic characteristics of heterozygous variant carriers were not remarkably different from those of noncarriers of CTEPH. However, both heterozygous variant carriers with CTEPH and homozygous variant carriers with PPS showed tortuous vessels on angiography.

21 September 2022 in General Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
PDF file
MNMasayuki Nishiyama
Masayuki Nishiyama
YIYosuke Inoue
Yosuke Inoue
HSHiroaki Sasaki
Hiroaki Sasaki
YSYoshimasa Seike
Yoshimasa Seike
TATatsuo Aoki
Tatsuo Aoki
TSTaichi Sakaguchi
Taichi Sakaguchi

15 March 2023 in Internal Medicine
Verified
Journal Article
Open access
PDF file
ATAkihiro Tsuji
Akihiro Tsuji
TMToshiyuki Miyata
Toshiyuki Miyata
ASAkihiro Sekine
Akihiro Sekine
RNReiko Neki
Reiko Neki
KKKoichi Kokame
Koichi Kokame
TOTakeshi Ogo
Takeshi Ogo
Antithrombin resistance (ATR) is a newly identified strong genetic predisposition to venous thromboembolism (VTE) caused by genetic variations in prothrombin with substitutions of Arg at position 596 with either Leu, Gln, or Trp. In the present report, we identified a missense variant p.Arg596Gln in 3 patients from 2 families with unprovoked VTE who each experienced their first VTE event at 19, 67, and 19 years old. The three patients did not show any positive markers for thrombophilia on routine testing, suggesting that patients with unprovoked VTE who have negative findings on thrombophilia tests may carry a prothrombin variant with ATR.

6 May 2025 in Journal of the American Heart Association
Verified
Journal Article
Open access
TKTakatoyo Kiko
Takatoyo Kiko
RARyotaro Asano
Ryotaro Asano
TITomohiko Ishibashi
Tomohiko Ishibashi
HEHiroyuki Endo
Hiroyuki Endo
SFShinya Fujisaki
Shinya Fujisaki
TOTakeshi Ogo
Takeshi Ogo
Background: The heterozygous ring finger protein 213 (RNF213) p.Arg4810Lys variant has been identified in patients with chronic thromboembolic pulmonary hypertension (CTEPH). This study aimed to clarify the influence of the RNF213 p.Arg4810Lys variant on the response to balloon pulmonary angioplasty (BPA) in patients with CTEPH. Methods: We retrospectively analyzed 93 patients with CTEPH who underwent BPA by analyzing the RNF213 p.Arg4810Lys variant. Clinical parameters and hemodynamics following BPA were compared between RNF213 p.Arg4810Lys variant carriers and noncarriers, along with BPA‐related complications. Results: Among 93 patients, 7 (8%) were heterozygous RNF213 p.Arg4810Lys variant carriers and 86 (92%) were noncarriers. Both groups showed significant improvements in mean pulmonary artery pressure and pulmonary vascular resistance following BPA. However, the 6‐minute walk distance, symptoms, cardiac index, and right ventricular function did not significantly improve in heterozygous RNF213 variant carriers, whereas noncarriers showed notable improvements. Group differences in mean change from baseline to follow‐up were significant in cardiac index (0.4 L/min per m 2 [95% CI, 0.1–0.8]; P =0.019), 6‐minute walk distance (70 m [95% CI, 6–135]; P =0.036), and right ventricular ejection fraction (9% [95% CI, 5–12]; P <0.001), all favoring noncarriers. Of the 515 BPA procedures, complications were significantly higher in variant carriers than in noncarriers (25% versus 8%; P <0.001). Multivariate logistic regression analysis indicated a significant association between the RNF213 p.Arg4810Lys variant and BPA complications (adjusted odds ratio, 7.0 [95% CI, 1.1–44.4]; P =0.038). Conclusions: Heterozygous RNF213 p.Arg4810Lys variant carriers exhibited a poor response to BPA, suggesting that the RNF213 p.Arg4810Lys variant could be a risk factor for BPA complications.